Sun Pharmaceutical to acquire Checkpoint Therapeutics for $355m.

Sun Pharmaceutical, an Indian multinational pharmaceutical company, agreed to acquire Checkpoint Therapeutics, a commercial-stage immunotherapy and targeted oncology company, for $355m. "Combining UNLOXCYT, an FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma, with Sun Pharma's global presence means patients with cSCC may soon have access to an important, new treatment option. The acquisition further bolsters our innovative portfolio in onco-derm therapy," Dilip Shanghvi, Sun Pharma Chairman & Managing Director.